Building a Structured Field within Clinical Notes in a Migraine Practice: A Quality Improvement Project by Moreno, Angel Leonel
UCLA
UCLA Electronic Theses and Dissertations
Title
Building a Structured Field within Clinical Notes in a Migraine Practice: A Quality 
Improvement Project
Permalink
https://escholarship.org/uc/item/3s3169rv
Author
Moreno, Angel Leonel
Publication Date
2020
 
Peer reviewed|Thesis/dissertation
eScholarship.org Powered by the California Digital Library
University of California
UNIVERSITY OF CALIFORNIA 
Los Angeles 
 
 
 
Building a Structured Field within Clinical Notes in a Migraine Practice: A Quality Improvement 
Project 
 
 
A dissertation submitted in partial satisfaction of the  
requirements for the degree of Doctor of Nursing Practice 
 
by 
 
Angel Leonel Moreno 
 
 
 
 
 
2020 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Copyright by 
Angel Leonel Moreno 
2020 
  
 ii 
ABSTRACT OF THE DISSERTATION 
 
Building a Structured Field within the Progress Note in Migraine Documentation:  
A Doctor of Nursing Practice Quality Improvement Project 
 
by 
 
Angel Leonel Moreno 
Doctor of Nursing Practice 
University of California, Los Angeles, 2020 
Professor Andrew C. Charles, Co-Chair 
Professor Wendie A. Robbins, Co-Chair 
 
 
Background: Documentation practices in an outpatient migraine clinic describe migraine 
and headache days (MHD) experienced per month in narrative form within an electronic health 
record (EHR). Narrative data is time consuming to use in clinic-based research (Meyers et al., 
2018). The Model of Improvement’s Plan-Study-Do-Act (PDSA) and the Chronic Care Model 
(CCM) guided the methodology of this QI project aiming to 1). build a structured field (SF) 
within an EHR clinical note, and 2). to describe the characteristics of patients who self-record 
and track their migraine days compared to those who do not. This work includes the first PDSA 
cycle. Methods: A MHD SF for the EHR clinical note was developed based on the literature 
review, clinical practice guidelines and informaticists consultation. Migraine clinical patients 
 iii 
were recruited and divided into two groups based on whether they kept a record of MHD in a 
diary or not. Participants completed a questionnaire assessing education level, income, and 
marital status. A chart review then quantified additional characteristics including age, sex, 
history of migraine medication use, MHD frequency and severity, age of migraine onset, and zip 
code. The documented migraine data will be input into the MHD SF once the SF is built. 
Results: The MHD SF is currently being built. A total of 52 patients have been enrolled for the 
feasibility portion of the project, 28 tracked MHDs and 24 did not. Migraine characteristics and 
demographic data were compared between the two groups. There were no statistically significant 
differences between the groups (p > 0.05) except for the number of preventives tried, which was 
higher in the documented MHD group (M =  8.89, SD = 5.32) compared to the group that did not 
keep a diary (M = 5.92, SD = 3.50), p=0.03. Conclusion: The COVID-19 pandemic delayed the 
construction of the MHD SF. Changes in clinic dynamics and patient access changed with 
COVID-19 which impacted the original feasibility portion of the work involving LVNs and 
patients. This QI project will improve therapy evaluation and facilitate clinic-based research. The 
PDSA and CCM provide the project practical and conceptual structure and supports the projects 
sustainability.  
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Chapter 1 
Introduction 
Migraine is a common neurologic condition affecting hundreds of millions of people 
around the world with significant sequelae that prevents those affected from living a better life. 
Finding a reliable and effective treatment, and eventually a cure, will improve the lives of 
millions of people. Improving migraine documentation in the electronic health record (EHR) by 
adding a structured field (SF) to better track migraine metrics, such as migraine headache days 
(MHD), will help achieve this aim by improving migraine therapy evaluation and facilitating 
clinic-based research. Migraine is highly prevalent around the world and the United States of 
America as one in six people in the United States suffer with migraine (Burch, Rizzoli, & Loder, 
2018) and is the seventh leading disorder worldwide (Global Burden of Disease, 2015). 
Therapies for the disorder have been variably effective and often poorly tolerated, leading to 
poor medication adherence and forcing patients to cycle through available medications to find 
relief. Migraine incurs significant direct and indirect costs for patients and industry and 
disproportionately affects women and vulnerable populations in lower socioeconomic statuses 
(SES). Effective and consistent documentation of therapeutic outcomes in a MHD SF will help 
patients and clinicians better understand therapeutic outcomes improve migraine patients’ quality 
of life (QOL).   
Migraine Therapy 
Patients with migraine use prophylactic approaches to prevent migraine attacks and acute 
therapies to treat migraine attacks when they occur. Preventive medications are considered 
effective if MHD are reduced by 50% or more within three months (Silberstein, 2015). A 
systematic review by Hepp, Bloudek, & Varon (2014) found migraine patients had poor 
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adherence to migraine prophylaxis and that adverse events caused by preventive medications was 
the most typical reason for discontinuation. Lipton et al. (2016) found that currently available 
acute therapies are commonly ineffective, with 56% of migraine survey participants reporting 
poor relief at 2 hours after taking a acute medication, and 53% of participants reporting poor 
relief in 24 hours. The same study found that, of the 44% of participants that did find adequate 
relief, 25% of them had another migraine attack within 24 hours (Lipton et al., 2016). A survey 
study of 1,165 migraine patients from around the world found that the average number of 
different medications ever used by patients with episodic migraine was M = 2.9, SD = 3.6, and M 
= 3.9, SD = 3.5 in patients with chronic migraine (Blumenfeld et al., 2013). Discontinuing acute 
medication can lead to negative consequences. About 80% of patients with migraine who 
completely discontinued acute therapies were unlikely to report being able to work or function 
normally with a headache (Lipton et al., 2019). Novel migraine therapies targeting the calcitonin 
gene-related peptide emerged in 2018 and have revolutionized the migraine field. The calcitonin 
gene-related peptide monoclonal antibody (CGRP MAB) drug class demonstrated a reduction of 
MHD per month by 50% or more in 50% of patients that received erenumab 140 mg/ml in the 
clinical trial setting (Goadsby et al., 2017). Quantifying clinical responses to established and 
novel therapies by documenting MHD SF within the EHR will improve medication adherence 
and restore hope in a patient  with migraine to live a less disabled life.  
Migraine Cost 
Migraine management carries a high monetary and QOL burden. Direct migraine costs 
have been estimated to be $9.2 billion per year (Raval & Shah, 2017). Chronic migraine, which 
is defined as 15 MHD a month or more by the International Headache Society (2018), is three 
times as expensive as episodic migraine (Messali et al., 2016). Indirect costs of migraine include 
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a 50% reduced work productivity (Munakata et al., 2009), lower reported QOL scores 
(Blumenfeld et al., 2011), and higher work absences and short-term disability costs (Gilligan et 
al., 2018). Migraine is commonly associated with lower SES, and given the associated expenses, 
can be an obstacle that prevents patients with migraine from achieving a higher SES. 
Migraine and Vulnerable Populations 
Migraine disproportionately affects women and vulnerable populations in lower SES. 
Migraine affects women three times as much as men (Vetvik & MacGregor, 2017), which is 
around 20% of women in the United States (Burch, Rizzoli, & Loder, 2018). Those in lower 
SES, such as the unemployed, those in a lower family income bracket, the elderly, and those with 
disabilities report higher migraine frequency compared to their more affluent counterparts 
(Burch, Rizzoli, & Loder, 2018). The American Migraine Prevalence and Prevention report 
demonstrated that household income predicted migraine risk because a household income of 
$90,000 and above reduced migraine risk by 50% (Lipton et al., 2007). Charleston et al. (2018) 
found that people living in areas of low SES reported more migraine disability and suggests 
increased stress caused by violence, food insecurity and lack of healthcare access as contributing 
factors. Befus, Irby, Coeytaux, and Penzien (2018) propose that migraine is a treatable condition 
and should be classified as a health equity issue because those who lack access to care 
experience worse outcomes. SES of parents directly predicts adult educations level of their 
children (Acacio-Claro, Doku, Koivusilta, & Rimpela, 2017) and Charleston and Heisler (2016) 
developed a theoretical model for Headache Literacy suggesting that lower education levels 
negatively affect headache literacy and self-care leading to worse headache outcomes. Finding 
effective therapies for migraine can lead to economic advantages for migraine patients and create 
a more equitable reality for them to achieve their goals. 
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The Los Angeles County Department of Public Health’s report of Key Indicators of 
Health by Service Planning Area (SPA) (2017) published a snapshot comparing health outcomes 
across the 8 SPAs (Appendix A). 
The Electronic Health Record and Structured Fields 
The Institute of Medicine (2003) recommended healthcare organizations to use an 
electronic health record (EHR) to promote patient safety and improve the quality and efficiency 
of care. The EHR has since become the standard of care in the United States health system and 
has improved trustworthiness between clinician and patient, improve patient safety and increase 
the efficacy of care (Ozair, Jamshed, Sharma, & Aggarwal, 2015). However, the structure in 
which data is documented into the EHR has not been standardized in clinical practices. 
Moreover, narrative, uncodified documentation is difficult to use for quality improvement 
projects or clinic-based research (Meyers et al., 2018), thus limiting the benefits achieved with 
an EHR. Clinicians miss the EHR’s full potential when narratively documenting clinical notes as 
if it was a paper chart. 
Clinical notes containing SF help providers document important information more 
consistently in a way that can be retrieved efficiently. Cicchini et al. (2016) improved cancer 
staging documentation from 28% to 60% over 12 months after having cancer staging attending 
physicians document in a structured note format that contained cancer staging specific SF. 
Neuroradiologists utilizing structured notes have demonstrated improved rates of documenting 
important findings in multiple sclerosis diagnosis and achieved a 100% radiologist utilization 
rate (Dickerson et al., 2017). Future goals utilizing SF within progress notes to track metrics is to 
leverage large codified data with biobanking and predict response to therapy for future patients 
(Meyers et al., 2018).  
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Clinician documentation practices in an academic migraine clinic in Southern California 
document notes in narrative and structured formats. The subjective section of the clinical note is 
documented in a narrative-only form, while current medications, vital signs and laboratory 
results are documented in an SF. Documenting subjective data in a narrative form does not 
leverage EHR features that help clinicians capture and track subjective metrics, such as MHD 
and acute medications doses used a month, migraine severity and duration, among other metrics, 
efficiently. Narrative data is free-text, uncodified data that is challenging to use for quality 
improvement projects and research (Meyers et al., 2018). A systematic review and meta-analysis 
found that effective utilization the EHR can improve the quality of healthcare by increasing 
efficiency and adherence to guidelines while decreasing medication errors and adverse drug 
(Campanella et al. 2015). Campanella et al. (2015) suggest that clinicians can enhance the 
benefit of the EHR by including a decision support system and expanding SFs.  
The reliability of subjective data documented in migraine notes depends on the accuracy 
of what patients report. Migraine patients can keep track of their MHD as a way to evaluate the 
efficacy of migraine therapies and documenting MHD reduces recall bias when reporting MHD 
per month (Torelli & Jensen, 2010). Tracking MHD is so critical in migraine research that the 
change in MHD a month is a primary end point when conducting randomized controlled trials of 
preventive treatments (Tassorelli et al., 2018). Furthermore, a systematic review evaluating 
psychological interventions for migraine found that 14 out the 19 studies selected used headache 
diaries as their dependent variables (Sullivan, Cousins, & Ridsdale, 2016). Traditionally, MHD 
were tracked using paper and pencil approaches, and now electronic methods of tracking MHD 
are available. Bandarian-Balooch, Martin, McNally, Brunelli, and Mackenzie found that short-
form migraine diaries and electronic migraine diaries had equivalent adherence when measuring 
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headache variables (2017). A systematic review by Ramsey et al. (2014) found that adherence 
rates to paper diaries were between 83% and 95% and adherence to electronic diaries was 90% in 
migraine patients. 
Provider documentation and patient self-monitoring practices vary, and this variation can 
yield inconsistent documentation quality. Variation in documentation styles between providers 
has been found to reduce efficacy and safety when documenting in EHRs (Cohen, Friedman, 
Ryan, & Richardson, 2019). Linder, Schnipper, and Middleton (2012) found that providers who 
dictated their notes had lower quality of clinical documentation compared to providers who 
documented in structured notes for the management of patients with coronary artery disease and 
diabetes. Solely narrative notes vary in documentation method and completion, can miss key 
clinical data, and make it difficult to determine evidence of meeting documentation quality 
measures (Edwards, Neri, Volk, Schiff, & Bates, 2014). While narrative sections of clinical notes 
are important, limiting the note within an EHR to be solely narrative is a missed opportunity. 
The ideal clinical note in migraine medicine has not been established in the literature. 
Marmura and Nahas (2010) discuss the advantages and disadvantages of using an EHR to 
document clinical notes and suggest that an ideal migraine clinical note would include the 
clinical plan from the previous note, a combination of SFs documenting MHD frequency and 
severity, weight, blood pressure and QOL indicators plus narrative free-text to describe findings 
not covered by the SF. Structured notes increase the quality of documentation and yield a more 
consistent note (Bink et al., 2018; Cecchini, Framski, Lazette, Vega, Strait, & Adelson, 2016; 
Narayanan et al., 2017; Simon et al., 2018; Simon et al, 2019; Meyers et al., 2018). In fact, the 
work by Maraganore et al. (2015) has improved documentation methods and their group is 
combining the improved note with DNA biobanking, paving the way for more precise medicine 
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that may lead to predicting responses to therapy in future patients. Rheumatology practices have 
incorporated Patient Reported Outcome Measurement Information System where patients can 
directly document clinical outcomes that generate into SFs within a clinical note, a strategy that 
has increased patient engagement and improved clinical outcomes (Schmajuk & Yazdany, 2017). 
Incorporating more SFs into clinical notes will allow providers to maximize the benefit an EHR 
can provide and may encourage patients to increase their participation in their healthcare by 
documenting directly into their chart. 
Documenting subjective data within the clinical notes of a migraine clinic in a narrative-
only format limits the EHRs ability to demonstrate the outcomes of the care provided and 
hinders clinic-based research. Adding an SF within the subjective section of a clinical note to 
document MHD per month exercises the EHR’s ability to better demonstrate the impact 
therapies have on MHD and increases documentation consistency between providers. This DNP 
scholarly QI project aimed to create a novel MHD SF in a migraine clinic’s EHR and to ascertain 
feasibility of having patients keep MHD diaries to supply more reliable MHD for the SF. The 
MHD per month data would be input into the MHD SF once built. This initial PDSA cycle only 
included patients seen by the PI.  
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Chapter 2 
Review of Literature 
A review of literature using the search terms, “structured” “data” “field” “discrete” 
“electronic medical record or electronic health record” “headache” “migraine” “neurology” 
“diary” “calendar” “quality improvement” and “meaningful use” was conducted in various 
combinations in the PubMed, Cumulative Index of Nursing and Allied Health Literature 
(CINAHL), and Web of Science data bases. The filters of humans, English and 10-year limit 
were added to the results of combinations from the above search terms. PubMed yielded the most 
results and 50 publications were chosen based on the abstracts if the abstracts included key terms 
that discussed structured notes. Further exploration of related publications and cited by 
publications from chosen abstracts produced an additional 25 publications. Of the 75 abstracts 
reviewed, 50 publications were read in detail and 20 were included in the review of literature. 
CINAHL produced six results and three of the publications were chosen for this project. Further 
research into similar articles and reviewing cited publications and a manual search of relevant 
bibliographies also helped uncover 5 pertinent publications. 
 Simon et al. (2019) built customized stroke-structured clinical documentation support 
into the EHR used in their practice. This paper is this author’s DNP scholarly project executed in 
a stroke clinic. The aim was to develop notes containing structured and free text fields. SFs 
included information on stroke events, such as the National Institutes of Health Stroke Scale, 
timing, presenting symptoms and locations of stroke events, residual deficits, stroke subtype, 
diagnostic work up and sequalae, as well as laboratory findings. Optional SFs included measures 
capturing disease impact and mood changes, such as the Barthel Index, Epworth Sleepiness 
Scale, and Short Test of Mental Status. Workflow processes had medical assistants document 
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patient self-reported items, cognitive testing was documented by registered nurses, and other 
pertinent data was documented by stroke neurologists. The research group met every 2 weeks 
with programmers to review ease of use and make modifications based on clinician and staff 
feedback. As of August 2018, 2,332 patients had been evaluated. Best Practice Alerts were 
created as hard stops depending on the scores and intervention for those scores needed to be 
documented. Change in patient outcomes has not been evaluated, but this work demonstrates 
feasibility of workflow and use of SFs in a stroke clinic.  
 Cecchini et al. (2016) conducted a quality improvement project utilizing the PDSA 
quality improvement framework, to improve cancer stage data capture. In this study an EHR was 
customized with a structured module that required physicians to enter a cancer stage. Primary 
outcomes were measuring the increase in use of the structured staging module. Secondary 
outcomes included physician responses to the process and to inquire why the process was not 
used. If staging could not be done, free text areas were available to describe the issue. PDSA 
cycles guided the intervention and primary outcomes were measured at 4, 8, and 12 months post-
intervention. This group found an increase in staging documentation from 28% to 60% after 12 
months demonstrating statistically significant improvement (p < 0.001) in rates of cancer staging. 
Limitations included lack of timely staging, the exclusion criteria of patients before 2014 and 
advanced practice participation such as nurse practitioners (NP) or physician assistants.  
  Meyers et al. (2018) created a note containing structured and narrative fields in order to 
improve quality and support practice-based research within a headache clinic. The note is 
currently being tested in 14 headache clinics throughout the United States and data on headache 
outcomes are pending. This quality improvement project structured General Anxiety Disorder 7-
item, Center for Epidemiology Studies Depression Scale and the Migraine Disability Assessment 
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questionnaire, among others. The developers of the tool met every 2 weeks for three months, 
although the methodology used to guide this project was mentioned they used principles from the 
model of improvement. The workflow created utilized a medical assistant to input patient-
reported data so face-to-face time with the neurologist was not changed. Cohort characteristics 
were analyzed once 100 patients with clean data were achieved and correlation between metrics 
and initial visits were compared. Dashboards measuring trends were created. Referrals to 
appropriate providers were carried out when patients screened positive for depression or anxiety. 
Data collection continues and will be published in the future. Limitations in this research include 
lack of tracking number of days a month affected by migraine, doses of acute medications taken 
per month or other QOL indicators. The Migraine Disability Assessment Scale does include this 
data, but frequent testing with the same tool incurs the risk of test-retest validity issues. This 
work does not address provider and staff response to the structured note.  
 The articles above demonstrate the feasibility of utilizing SFs in multiple clinical 
environments. Strategies to reduce undue burden on providers using structured notes were 
explored and avoided reducing face-to-face time between patients and providers. The articles 
above described methods of avoiding pitfalls associated with structured notes. The Model of 
Improvement was helpful in guiding this type of documentation QI project. Adding SFs into a 
clinical note within a migraine practice is feasible and allows for the creation of dashboards and 
clinic-based research. Gaps in the published studies include failure in measuring the patient’s 
ability to account for migraine days using migraine calendars and describing the clinical provider 
and staffs experience with the SF.  
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Chapter 3 
Theoretical Models 
The Model for Improvement will be used to guide the process of this DNP scholarly QI 
project and the Chronic Care Model will provide the theoretical context that guided the 
development of this project. The Model for Improvement applies five principles for 
improvement; 1. Knowing why you need to improve, 2. Having a feedback mechanism to tell 
you if the improvement is happening, 3. Developing an effective change that will result in 
improvement, 4. Testing a change before attempting to implement, and 5. Knowing when and 
how to make the change permanent (Langley et al., 2009). The model is comprised of two 
sections, the first of which asks three questions; 1. What are we trying to accomplish, 2. How 
will we know that a change is an improvement, and 3. What change can we make that will result 
in improvement (Langley et al., 2009)? The second section is comprised of plan-do-study-act 
(PDSA) cycles used to test changes, determine if a change is an improvement, alter the change if 
needed, then re-evaluate (Langley et al., 2009). Melnyk and Morrison-Beedy (2019) outline the 
PDSA cycle where; 1. The plan phase consists of creating a plan once an improvement project 
has been identified, 2. The do phase implements the plan created on a small scale, 3. Results of 
the do phase are analyzed in the study phase, and 4. Changes based on results are implemented 
into a new plan and the cycle starts again at a larger scale. After the fourth PDSA cycle, the 
process of permanence is started and the change can spread if applicable (Langley et al., 2009). 
This scholarly project is the first round of PDSA on the journey to eventually spread this 
documentation style using the MHD a month SF as the standard documentation practice in a 
migraine clinic after evaluating its impact on migraine documentation.  
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 The Chronic Care Model (CCM) addresses quality gaps associated with the demands a 
chronic condition exerts on a health system. Migraine is a chronic disorder that has acute 
episodes and the CCM is an appropriate model to address this condition. The CCM aims to 
change a reactive healthcare system to a proactive one, anticipating the needs of patients with 
chronic illness by increasing patient self-management, integrating decision support into provider 
practice, and providing information technology (Coleman, Austin, Brach, & Wagner, 2009). This 
scholarly project utilizes these guiding points in developing the SF to document migraine and 
headache days, tailoring migraine documentation to the migraine population.  
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Chapter 4 
Methods  
 This DNP scholarly QI project aimed to create a novel MHD SF in a migraine clinic’s 
EHR and to ascertain feasibility of having patients keep MHD diaries to supply more accurate 
MHD for the SF. The MHD per month data would be input into the MHD SF once built. This 
initial PDSA cycle only included patients seen by the NP Principal Investigator.  
The novel COVID-19 pandemic altered this project’s original timeline and methodology 
and the PI adjusted the original methodology in order to continue the endeavor. At the beginning 
of the QI project the author began building the MHD SF in collaboration with IT. There were a 
series of meetings with stakeholders, which included patients, migraine specialists, the clinic 
manager, the medical director, the licensed vocational nurses (LVNs), and IT. However, the 
pandemic changed the time line once informaticists were pulled by the hospital system to build 
COVID-19 smart phrases, shortcuts, and optimization. The author resumed building the MHD 
SF on April 22, 2020 in collaboration with informaticists and migraine clinicians. 
Originally, patients were going to be asked to keep MHD per month data and present that 
data to the LVNs, who would then input that data into the MHD SF, and the field would populate 
into the NP’s note. The migraine clinic currently sees migraine patients for follow up via 
telemedicine in order to reduce the spread of the novel virus, thus patients are not interacting 
with the LVNs at the moment. The PI planned to train the LVN’s to document MHD in the SF.  
The Structured Field Staff Satisfaction Questionnaire (SFSSQ), a three question, 1-5 
Likert scale questionnaire and a write-in section for additional comments was to be administered 
to the LVN and NP staff at the end of the current PDSA cycle (Appendix B). Responses would 
help identify areas of improvement for the MHD SF before initiating the second PDSA cycle, 
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which will open patient enrollment opportunity to patients seen by the NP and two fellow 
physicians. The SFSSQ was omitted since the MHD SF has not been completed. 
The NP Principal Investigator lost patients prepared to participate in this QI project 
because some patients lost access to the migraine clinic once they became unemployed and lost 
their health insurance. Other patients were lost to follow up when the migraine clinic triaged 
patients, maximizing telemedicine follow up and limiting the number of patients coming to the 
migraine clinic. Patients typically seen by the NP for procedures were transferred to the 
attending physicians schedules for those procedures. Patients typically managed by attending 
physicians were scheduled with the NP for telemedicine appointments. Many of the 
appointments with the NP became emergent visits trying to keep patients from going to the ER 
due to migraine.  
 Prior to the pandemic, the NP Principal Investigator averaged 40 to 50 patients a week. 
Clinic visits decreased significantly after the pandemic started, ranging between 10 to 25 
consultations per week. Patients with severe migraine are scheduled at a higher frequency, seen 
every two to four weeks and patients that do not require therapy changes are seen once every 
three to six months.  
Revised Methodology 
Participants 
 The influx of patients typically seen by attending physicians into the PI’s schedule 
presented an opportunity to enroll participants in the QI project based on whether they either 
documented or did not document MHD per month. Convenience sampling included recruiting 
migraine patients within an academic migraine telemedicine clinic in Southern California. 
Inclusion criteria were: being a patient of the clinic’s NP (PI on this QI project), age 18 years and 
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older, having a diagnosis of migraine, with or without aura, or chronic migraine, as defined by 
the International Classification of Headache Disorders-3 (International Headache Society, 2018), 
and volunteering to participate in this QI project by filling out an online questionnaire. Exclusion 
criteria included patients in the clinic not seen by NP, clinic patients seen by NP that do not have 
a diagnosis of migraine with or without aura or chronic migraine, migraine patients with 
comorbid chronic daily headache, and migraine patients who chose not to participate.  
Instruments 
 The Migraine Demographic Data Questionnaire (MDDQ) is a two-part questionnaire 
developed by the PI to tabulate demographic and migraine characteristics (Appendix C for part 
1; Appendix D for part 2). The first part of the MDDQ was completed by patients who met 
inclusion criteria and agreed to participate. This part of the MDDQ collected marital status, 
highest education level, income range and preferred healthcare language not systematically 
documented in the EHR. These variables were codified to facilitate analysis (Appendix E).  
Part two of the MDDQ quantified migraine characteristics through a manual chart review 
completed by the PI. The following migraine characteristics were collected in the chart review: 
age, gender, zip code, type of insurance – commercial or federal/state sponsored, age of migraine 
onset, number of preventive and acute medications ever used, and number of preventive and 
acute medications currently used. The last documented blood pressure, weight, height, average 
MHD per month, and average severity of migraine attacks were also migraine variables 
tabulated. These variables were codified to facilitate analysis (Appendix F). All variables of 
interest in this QI project have been reported to directly or indirectly influences migraine risk 
(Blumenfeld et al., 2013; Burch, Rizzoli, & Loder, 2018; Charleston et al., 2018; Hepp, Bloudek, 
& Varon, 2014; Messali et al., 2016; Vetvik & MacGregor, 2017). 
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Definitions 
The International Classification of Headache Disorder, 3rd edition, definition of a 
headache day was used which is the “number of days during an observed period of time affected 
by headache for any part or the whole day” (International Headache Society, 2018), to define 
MHD in this work. 
Preventive medications are defined as medications “used to reduce the frequency, 
duration, or severity of attacks” by Silberstein (2015), and is the definition used for preventive 
medications in this work. Standard migraine preventive medication classes include anti-epileptic 
(depakote, gabapentin, topiramate), antidepressant (TCA, SSRI, SNRI), betablocker (atenolol, 
labetalol, propranolol), calcium channel blocker (verapamil, nicardipine, flunarizine), serotonin 
antagonist (cyproheptadine, pizotifen), select nonsteroidal anti-inflammatories (NSAID) 
(Celebrex and meloxicam only), and botulinum toxin (Botox, Xeomin, Myobloc) medication 
classes (Siberstein, 2015). Atypical preventive medication classes include alpha-adrenergic 
agonists (clonidine, tizanidine, guanfacine), ACEI (lisinopril, enalopril, captopril), ARB 
(candesartan, telmisartan) and the NMDAR antagonists (memantine) drug classes (Rau & 
Dodick, 2019). The CGRP MAB medication class (erenumab, fremanezumab, galcanezumab, 
and eptinezumab) is the first medication class to be developed specifically as a migraine 
preventive (Ceriani, Wilhour, & Silberstein, 2019). Prior to the CGRP MABs, every medication 
used to prevent migraine was developed for other conditions, found to reduce migraine disability 
in some patients with migraine, and secondarily adopted as migraine prophylaxis (Charles, 
2018). Migraine clinicians have the opportunity to demonstrate the life enhancing effects of the 
new therapies and the MHD SF will aid them in doing so.  
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Acute medications in migraine are defined as, “acute therapy taken to relieve the pain of 
migraine attacks” (Becker, 2015)  and is the definition used for acute medication in this work. 
Acute medications include acetaminophen, NSAID (ibuprofen, indomethacin, nabumetone, 
naproxen, diclofenac, ketorolac, etodolac, mefenamic acid, aspirin) , triptans (sumatriptan, 
rizatriptan, zolmitriptan, eletriptan, almotriptan, naratriptan, frovatriptan), triptan-NSAID 
combinations (treximate), ergotamines (methelergonavine, migranal), and medication 
combinations that include butalbital (fioricet, fiorinal) or caffeine (excedrin, 
aceminophen/caffeine) (Becker, 2015). Antiemetics (ondansetron, prochlorperazine and 
metochlopramide) (Lew & Punnapuzha, 2020) and muscle relaxers (cyclobenzaprine, baclofen) 
were considered to be acute medications in migraine therapy for the purposes of this work. The 
ditan (lasmitidan) and gepant (ubrogepant and rimegepant) (Ceriani, Wilhour, & Silberstein, 
2019) medication classes debuted in 2020 and are counted as acute medications in this work. 
Medication classes targeting the CGRP pathways seem to exhibit both preventive and acute 
properties (Charles, 2019), thus defining where the agents will be classified is important for this 
work. 
Most of the migraine variables tabulated were found in SFs within the participants’ 
charts. Three variables tabulated in this QI project, the age of migraine onset, MHD per month, 
and the average severity of migraine attacks as measured by the 1-10 numerical scale, were 
found in narrative data documented in clinic visits. Variations of each medication dose and route 
were counted as one. For example, sumatriptan 100 mg tablets, sumatriptan 20 mg/ml nasal 
spray, and sumatriptan 6 mg/ml subcutaneous injections count as one.  
Insurance type was categorized into two groups; commercial, such as HMO and PPO 
insurances, and state or federally sponsored insurance, such as Medicare, medical, or Tricare.   
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Blood pressure was measured in mmHg. Weight was measured in pounds, height was 
measured in inches, and pain severity was measured on a 0-10 numerical pain scale.   
Zip codes were categorized into their respective SPA (Los Angeles County, 2002). SPA 
distribution was analyzed and compared between the two migraine groups to explore for 
differences.  
Data Analysis 
Stata 15.1 was used to analyze the data collected. Data were checked for valid coding. 
The questionnaire responses and chart review data were summarized using descriptive statistics: 
mean/standard deviation for continuous data such as age, weight, and height; and 
frequency/percent for categorical data such as marital status, education level, and income 
category. Chi square (2) tests, Wilcoxen rank-sum (Mann-Whitney U) tests, and two sample t 
tests were used to compare the group of patients who recorded their MHD to those who did not 
on the demographic and migraine characteristics. A p-value <0.05 was considered statistically 
significant.   
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Chapter 5  
Results 
The MHD SF remains under construction. Of the 100 patients that met inclusion criteria 
during the QI time period, 40 choose not to participate and 8 had a diagnosis of chronic daily 
headache as well as chronic migraine. Fifty-two participants were enrolled in the study. A total 
of 28 participants reported keeping MHD diaries and 24 did not keep diaries. Participants kept 
track of MHD in a varieties of ways (Appendix G). Some participants kept a tally of the number 
of attacks that occurred a month, others kept a calendar where they documented MHD and 
treatments used per attack, and others used an application to help them keep track of migraine 
days where they documented duration and most bothersome symptoms. The systematic 
documentation of most bothersome symptoms would be useful in the evaluation of therapeutic 
approaches.  
No difference in migraine characteristics and demographics was found between the two 
groups (with alpha equal to 0.5 criterion), except for the number of preventive medications 
ordered ever, which was higher in the MHD documentation group, p = 0.03. The migraine group 
that documented MHD tried more preventive therapies in the past (M 8.7 SD 5.3) versus the 
group that did not document (M 5.9 SD 3.5), z = 2.2, p=0.03. 
The participants unanimously reported English as their health care language. There were 
mostly women (85%), the most frequently reported education level completed was a bachelor’s 
degree (44%), almost half of the participants reported a household income less than $75,000 per 
year (46%), and almost half reported being married (44%). The average age was 46 years (SD = 
18.5), and a majority had commercial insurance (81%).  
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The Los Angeles County Department of Health published health outcomes for the eight 
SPA regions in Los Angeles County (2017) (Appendix A), therefore, categorizing zip codes into 
their respective SPA regions gives insight to health factors and general outcomes of people living 
in those regions. Analysis comparing the distribution of SPA regions per group did not find 
statistically significant differences. When comparing the two groups after excluding zip codes 
not in Los Angeles County, no statistical difference were detected. This analysis did reveal the 
cohorts most common SPA regions, 2 (18.9%), 4 (16.2%), and 5 (46%), low represented regions, 
1 (5.4%), 6 (5.4%) and 8 (8.1%), and regions with no representation, 3 and 7. 
 
 
Table 1: Means (M) and standard deviations (SD) for continuous migraine variables for all 
participants, group that documented MHD and group that did not document MHD.  
 All participants 
M (SD) N = 53 
Documented MHD  
M (SD) n = 28 
Did not document MHD 
M (SD) n = 24 
Blood Pressure, Systolic 121.1 (15.6) 120.3 (15.8) 122.2 (15.6) 
Blood Pressure, Diastolic 77.21 (7.8) 76.5 (8.1) 78 (7.6) 
Weight, pounds 155.1 (46.8) 143.9 (35.1) 168 (55.6) 
Height, inches 65.1 (3.7) 65.57 (3.8) 64.45 (3.6) 
Age (years) at migraine 
onset 
21.3 (14.5) 21.2 (14.5) 21.46 (14.7) 
Migraine frequency,  
days per month 
10 (8.3) 10 (7.7) 10 (9.1) 
Migraine severity, 1-10 
scale 
4.8 (2) 5.1 (1.8) 4.5 (2.2) 
All preventives tried 7.5 (4.8) 8.9 (5.3) 5.9 (3.5)* 
Current preventives  2.5 (1.7) 2.4 (1.8) 2.5 (1.7) 
All acute therapies tried  8.1 (4.5) 8.6 (4.7) 7.4 (2.1) 
Current acute therapies.   2.7 (1.8) 2.4 (1.5) 3.1 (2.7) 
* t(50) = 2.2, p = 0.03 
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Table 2: Highest education completed for all participants, group that documented MHD and 
group that did not document MHD. 
Education, 
highest level 
completed 
All participants 
M (SD) N = 53 
Documented 
MHD  
M (SD) n = 28 
Did not 
document MHD 
M (SD) n = 24 
High School 14 (26.9%) 7 (25%) 7 (29.2%) 
Bachelor’s 
degree 
22 (42.3%) 13 (46.4%) 9 (37.5%) 
Graduate degree 13 (25%) 7 (25%) 6 (25%) 
Doctoral degree 1 (1.9%) 0 (0%) 1 (4.2%) 
Post-Doctoral 
degree 
2 (3.9%) 1 (3.6%) 1 (4.2%) 
2 = 1.5, df = 4, p = 0.9. 
 
 
Table 3: Income reported for all participants, group that documented MHD and group that did 
not document MHD. 
Income, 
thousands of 
dollars per year 
All participants 
M (SD) N = 53 
Documented 
MHD  
M (SD) n = 28 
Did not 
document MHD 
M (SD) n = 24 
Under 15 
 
2 (3.9%) 1 (3.6%) 1 (4.2%) 
15 – 24.999 
 
0 (0%) 0 (0%) 0 (0%) 
25 – 34.999 1 (1.9%) 0 (0%) 1 (4.2%) 
35 – 49.999 5 (9.6%) 2 (7.1%) 3 (12.5%) 
50 – 74.999 7 (13.5%) 3 (10.7%) 4 (16.7%) 
75 – 99.999 
 
9 (17.3%) 6 (21.4%) 3 (12.5%) 
100 – 149.999 6 (11.5%) 4 (14.3%) 2 (8.3%) 
150 – 199.999 10 (19.2%) 6 (21.4%) 4 (16.7%) 
200 or more 12 (23.1%) 6 (21.4%) 6 (25%) 
2 = 3.1, df = 7, p = 0.9, Fishers Exact p = 0.9 
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Table 4: Marital status reported for all participants, group that documented MHD and group that 
did not document MHD. 
Marital Status All participants 
M (SD) N = 53 
Documented 
MHD  
M (SD) n = 28 
Did not 
document MHD 
M (SD) n = 24 
Single 16 (30.8%) 10 (35.7%) 6 (25%) 
Married 23 (44.2%) 13 (46.4%) 10 (50%) 
Domestic 
Partnership 
4 (7.7%) 1 (3.6%) 3 (12.5%) 
Widowed 2 (3.9%) 2 (7.1%) 0 (0%) 
Divorced  6 (11.5%) 2 (7.1%) 4 (16.7%) 
Separated 
 
1 (1.9%) 0 (0%) 1 (4.2%) 
2 = 5.8, df = 5, p = 0.3, Fishers Exact p = 0.4 
 
 
 
 
 
Table 5: Gender category listed in chart for all participants, group that documented MHD and 
group that did not document MHD. 
Gender All participants 
M (SD) N = 53 
Documented 
MHD  
M (SD) n = 28 
Did not 
document MHD 
M (SD) n = 24 
Female 44 (84.6%) 24 (85.7%) 20 (83.3%) 
Male 8 (15.4%) 4 (14.3%) 4 (16.7%) 
Other 0 (0%) 0 (0%) 0 (0%) 
2  = .06, df = 1, p = 0.8. 
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Table 6: Insurance type listed in chart for all participants, group that documented MHD and 
group that did not document MHD. 
 
 
 
 
 
2 = 1.3, df = 1, p 
= 0.3. 
 
Table 7: Last documented migraine severity found in chart for all participants, group that 
documented MHD and group that did not document MHD. 
Migraine 
severity, 1-10 
scale. 
All participants 
M (SD) N = 53 
Documented 
MHD  
M (SD) n = 28 
Did not 
document MHD 
M (SD) n = 24 
0 0 (0%) 0 (0%) 0 (0%) 
1 0 (0%) 0 (0%) 0 (0%) 
2 6 (11.5%) 2 (7.1%) 4 (16.7%) 
3 11 (21.2%) 4 (14.3%) 7 (29.2%) 
4  10 (19.2%) 6 (21.4%) 4 (16.7%) 
5 5 (9.6%) 4 (14.3%) 1 (4.2%) 
6  7 (13.5%) 5 (17.9%) 2 (8.3%) 
7 7 (13.5%) 5 (17.9%) 2 (8.3%) 
8 5 (9.6%) 1 (3.6%) 4 (16.7%) 
9 1 (1.9%) 1 (3.6%) 0 (0%) 
10 0 (0%) 0 (0%) 0 (0%) 
2 = 8.8, df = 7, p = 0.3. The 0-10 pain scale asks patients to rate their pain, 0 meaning no pain, 1 
and 2 meaning mild, 3 and 4 meaning tolerable, 5 and 6 meaning very distressing, 7 and 8 
meaning very intense, 9 and 10 meaning excruciating/unbearable (Jensen, Turner, Romano, & 
Fisher, 1999).  
Insurance All participants 
M (SD) N = 53 
Documented 
MHD  
M (SD) n = 28 
Did not 
document MHD 
M (SD) n = 24 
Commercial 42 (80.8%) 21 (75%) 21 (87.5%) 
State or 
Federally funded 
10 (19.2%) 7 (21%) 3 (12.5%) 
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Table 8: Analysis of zip codes categorized by SPA regions for all participants, group that 
documented MHD and group that did not document MHD. 
Service Planning 
Area 
All participants 
M (SD) N = 53 
Documented 
MHD  
M (SD) n = 28 
Did not 
document MHD 
M (SD) n = 24 
1 2 (3.6%) 0 (0%) 2 (8.3%) 
2 7 (13.5%) 5 (17.9%) 2 (8.3%) 
3  0 (0%) 0 (0%) 0 (0%) 
4 6 (11.5%) 2 (7.1%) 4 (16.7%) 
5  17 (32.7%) 10 (35.7%) 7 (29.2%) 
6 
 
2 (3.8%) 1 (3.6%) 1 (4.2%) 
7 0 (0%) 0 (0%) 0 (0%) 
8 3 (5.8%) 2 (7.1%) 1 (4.2%) 
9 - Not in Los 
Angeles County 
15 (28.9%) 8 (28.6%) 7 (29.2%) 
2 = 4.6, df = 6, p = 0.6. 
 
Table 9: Analysis of zip codes categorized by SPA regions within Los Angeles County only for 
all participants, group that documented MHD and group that did not document MHD. 
Service Planning 
Area 
All Participants 
M (N = 37)  
Documented 
MHD  
M (n = 20) 
Did not 
document MHD 
M (n = 17) 
1 2 (5.4%) 0 (0%) 2 (11.8%) 
2 7 (18.9%) 5 (25%) 2 (11.8%) 
3  0 (0%) 0 (0%) 0 (0%) 
4 6 (16.2%) 2 (10%) 4 (23.5%) 
5  17 (46%) 10 (50%) 7 (41.2%) 
6 
 
2 (5.4%) 1 (5%) 1 (5.9%) 
7 0 (0%) 0 (0%) 0 (0%) 
8 3 (8.1%) 2 (10%) 1 (5.9%) 
2 = 4.6, df = 5, p = 0.5. 
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Chapter 6 
Discussion 
This DNP scholarly project was a documentation practice improvement QI project. It 
represents the first PDSA cycle of building and documenting MHDs in a MHD SF. This PDSA 
cycle started with patient participants managed by the PI, who is an NP. A MHD SF for the EHR 
clinical note was developed and is being built. The feasibility of having patients keep diaries to 
supply data needed for the MHD SF was demonstrated with 52 patient participants, 28 who 
historically recorded their MHD and 24 who did not. When demographic and migraine 
characteristics were compared between the two groups, no statistically significant differences 
were found in anthropomorphic characteristics, such as blood pressure, height, and weight, or in 
migraine characteristics, such as age of migraine onset, migraine frequency and severity or 
number of acute medications tried, or current use of preventive and acute medications. The group 
that tracked MHD met statistical significance for having more preventive medications tabulated 
from the medication tab than the group that did not track MHDs (M = 8.9, SD = 5.3 v. M = 5.9, 
SD = 3.5, respectively). Participants that recorded MHDs may have been more systematic in 
their approach to migraine therapy and cycled through preventive medications faster in order to 
reduce migraine’s impact, resulting in more preventive medications found on chart review.  
Participant characteristics in this migraine clinic reflected what has been described in 
migraine literature regarding the gender most affected, and migraine’s cost and impact on QOL. 
Most of the participants were women (85%), many cycled through preventive (M = 7.5, SD = 
4.8) and acute (M = 8.1, SD = 4.4 ) medications, almost all currently used preventive (M = 2.5, 
SD = 1.7) and acute (M = 2.7, SD = 1.8) medications. This echoes the financial impact of 
migraine therapy, and the migraine days per month frequency (M = 10, SD = 8.3) and severity 
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(M = 4.8, SD = 2) provides insight into migraine’s impact on the participants QOL. Of note, one 
participant who met criteria for preventive therapy had no current preventive medications listed 
in the chart, as counted by the methodology used in this QI project, and was an outlier in 
adhering to current migraine preventive therapy recommendations (Silberstein, 2018; Charles 
2018). Upon further investigation, the participant incorporates non-pharmacologic and lifestyle 
approaches to reduce migraine’s impact. This illustrates the need for documenting non-
pharmacologic approaches in a systematic manner within the EHR.   
Participants in this study were diverse in SES elements, but overall the participants 
reported features belonging to a higher SES. This is evidenced by the reported highest education 
level achieved; bachelor’s (42%), graduate (25%), doctoral (2%) and post-doctoral (4%) 
(totaling 73%), the majority of participants reported earning more than $100,000 per year (54%), 
most having commercial insurance (81%), and most having zip codes in more affluent SPA 
regions, 2 (19%) and 5 (46%) totaling 65%.  
A majority of participants with zip codes in Los Angeles County lived in SPA regions 2 
(19%), 4 (16%), and 5 (46%) (totaling 81%). Of these three SPA regions, 2 and 5 are reported to 
have better health outcomes than 4, as reported by the Los Angeles County Department of Public 
Health, Office of Health Assessment and Epidemiology report (2017) (Appendix A). SPA 2 is 
reported to have low housing instability, adult obesity and type 2 diabetes and high percentage of 
adults exercising in their neighborhood. SPA 5 is reported to have low difficulty accessing 
medical care, adult obesity, smoking cigarettes and number of days that poor health limited 
physical activity and high percentage of feeling safe from crime, adults exercising and being 
insured. In contrast, SPA 4 is reported to have low rates of insured adults, high rates of difficulty 
accessing medical care and adults living with depression The disproportionate enrollment of 
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participants from SPA regions 2, 4, and 5 may be due to location of the migraine clinic, which is 
in SPA five, or other socioeconomic factors, such as having reliable transportation, access to 
healthcare, or having knowledge that specialized care for migraine exists. Low or no 
representation from SPA regions 1, 3, 6, 7, and 8 may indicate an unmet need in managing 
migraine in these regions.  
Limitations 
The beta version of the MHD SF developed in this PDSA cycle (Appendix H) will be 
completed in collaboration between migraine specialists and informaticists. Published literature 
has not quantified  changes in therapeutic outcomes in migraine clinics that document migraine 
characteristics in SFs. This field of study remains to be explored and findings published.  
While the current participant sample is small and lacks the necessary power to draw 
definitive conclusions, this QI project has generated new queries to be explored, such as new 
migraine characteristics to trend and new medication designations to consider. Given the small 
data set from one migraine clinic, and the multiple comparisons, these findings need to be 
retested with a larger sample to explore queries generated. Since this project collected, tabulated 
and described various migraine characteristics in participants from one migraine clinic, the 
findings cannot be generalized to other migraine clinics. The COVID-19 pandemic presented 
pandemic scale challenges. The author navigated the project while adjusting to clinical demands 
and adjusted the methodology in order to continue the project.   
The methodology used to tabulate past and current medications was completely 
dependent on the medication listed in the medication history tab of the EHR. Limiting the count 
of preventive and acute approaches to the medication history tab did not include non-medication 
approaches used to prevent or resolve migraine. Lifestyle behaviors such as regular exercise, 
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meal intervals, caffeine use and sleep habits are therapeutic staples in migraine management 
(Charles, 2018), and were not counted as a preventive or acute approach. A secondary analysis of 
the United States 2012 National Health Interview Survey by Zhang et al., (2017) found that 3% 
of patients with migraine reported using complementary and alternative modalities (CAM), such 
as receiving acupuncture and chiropractic treatments, inhaling and applying essential oils, and/or 
ingesting herbal supplements specifically for migraine management. Interest in non-invasive, 
percutaneous neuro-modulatory devices has increased in the last decade and novel devices have 
been approved by the United States Food and Drug Administration. The type of energy and 
frequency of energy type vary among neuro-modulatory devices, some deliver single-pulsed 
transcranial magnetic stimulation and others emit electrical current stimulation, that have been 
shown to reduce migraine disability (Grimsrud & Singh, 2018). Lifestyle, CAM and neuro-
modulatory approaches are not systematically documented in this clinic, thus were not included 
in the preventive or acute therapy tabulation. Other limitations identified in this QI project is in 
methodology used to tabulate different doses and routes of the same medication because the 
various routes and doses were counted as one. The PI did not count IV fluid noted in the 
medication tab as an acute treatment because it was not clear if the order was for fluid 
resuscitation due to migraine, or for surgical indications. The medication count in this QI project 
under represents the true number of medications and therapies ever tried and currently used.  
Future opportunities 
This QI project has inspired ideas for more areas of migraine exploration. Future PDSA 
cycles should address the methodologic limitations discussed above; determining the method of 
tabulating various doses and routes of medications, categorizing lifestyle, CAM and neuro-
modulatory approaches as acute, preventive, or both, and determine if IV fluid should be counted 
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as an acute medication. Adding a category of medication that is simultaneously preventive and 
acute therapy, such as medications modulating the CGRP system, CAM approaches, and neuro-
modulatory devices considered both preventive and acute treatment would be of benefit. Another 
analysis of interest is exploring the relationship between migraine onset and tracking MHDs.  
Future iterations of this QI project can increase the number of SFs built to aid in 
systematic documentation of migraine characteristics. Characteristics of interest can include the 
date of initial clinic visit, the severity and frequency of migraine attacks during the initial visit, 
average duration of migraine attacks, and most bothersome migraine symptoms. The need to 
systematically document lifestyle, CAM and neuro-modulatory approaches used to manage 
migraine has been demonstrated in this QI project. Other SFs can be created to facilitate 
documenting characteristics helpful in evaluating responses to acute treatments such as the 
length of time it takes to terminate a migraine attack and side effects experienced from the acute 
therapy.  
Further analysis of participant characteristics with a larger data set may help illuminate 
the relationship between SPA region and migraine disability. It is likely that those with zip codes 
from SPA regions with worse health outcomes are disproportionately affected by migraine. The 
52 patients in the study sample were not representative of all SPA regions. A better 
understanding of patients SPA regions can guide the clinic’s approach in patient recruitment as 
well as inform clinicians of the challenges patients with migraine face in their SPA region.  
The current use of SFs to document migraine characteristics in this clinic are limited to 
past medical history diagnoses, review of systems, medications, blood pressure, heart rate, 
weight, height, body mass index, temperature, and pain level on the 1-10 pain scale. This is an 
area in documentation practices that is prime for further development. The evolution of this QI 
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project can eventually include linking therapeutic outcomes to genetic traits, which is currently 
being done in the NorthShore health system (Meyers et al., 2018), in order to develop the 
capability to predict responses to migraine therapy. This form of documentation can also spread 
to other medical practices who manage chronic conditions with acute exacerbations, such as 
other neurology practices, and even pulmonology and cardiology practices managing asthma, 
COPD and CHF, as well as the primary care setting.  
Conclusion 
 Migraine continues to affect hundreds of millions of people around the world despite 
advances in migraine pathophysiology understanding and the development of novel therapies. 
Finding reliable and effective treatments, and eventually a cure, will improve QOL, reduce the 
disability caused by this neurologic condition, and reduce a barrier for patients to achieve their 
full potential. Documentation of migraine characteristics is essential in the practice of migraine 
medicine and is indispensable in the evaluation of therapies. Improving the structure in which 
migraine data is recorded within the EHR will help clinicians leverage one of the EHRs function 
in retrieving characteristic documented in SF and trend changes overtime. This QI project began 
the process to facilitate the migraine clinicians ability to efficiently document MHDs per month 
within a SF in the EHR. This will help support clinical decision making to either continue or 
change treatments. Building a SF to document subjective variables adds value to medical 
practices that manage chronic health conditions accompanied by acute exacerbation, such as 
migraine and epilepsy. Building a SF encourages and facilitates providers to document important 
data consistently, increasing the rate of documenting variables of interest, and result in a more 
consistent note among providers. A SF enables the EHR to extract variables of interest, 
facilitating clinic-based research and demonstrate change of a variable over time. The EHR has 
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the capability to visually demonstrate the change in variables of interest if they are documented 
in SFs.  
Gaps that remain in using the MHD SF include building the MHD SF, documenting 
MHD in the field, tracking changes in MHD over time, evaluating the MHD SF contribution to 
improved MHD documentation and explore its impact in aiding clinicians and patients to 
determine whether or not to continue with a treatment course or not. This QI project also 
explored the published literature utilizing SF and described the process of building a MHD SF in 
this migraine clinic. 
In addition to beginning the process of developing a novel MHD SF in a migraine clinic, 
this QI project successfully described select migraine characteristics of participants who 
documented MHDs compared to those who did not. Statistical analysis demonstrated that both 
groups were similar, except that the number of preventives tried was higher in the group that 
tracked MHDs. While a larger sample size would be needed to better detect differences in 
migraine characteristics between the groups created, this QI project demonstrated the feasibility 
of describing migraine characteristics of patients in this clinics and is another step in improving 
the clinician’s understanding of their patient population. Better understanding of patients may 
help clinicians build a therapeutic report with those they serve and custom tailor migraine 
treatments that will hopefully lead to better migraine control. Future analysis to better understand 
the impact of SPA regions on migraine can help clinicians link the patients environment to health 
outcomes. Continuing this project will uncover more areas of improvement to better serve 
patients and cure migraine. Documenting notes narratively limits the EHR’s ability to track 
changes in migraine characteristics and is not an efficient way to use the EHR. A SF built to 
document MHDs in a clinical note bridges the documentation gap and will increase the 
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efficiency and validity of MHD documentation. Future studies demonstrating migraine outcomes 
after implementing this documentation intervention are needed to demonstrate value added.   
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Appendix A 
County of Los Angeles Service Planning Area (Los Angeles County Department of Public 
Health, Office of Health Assessment and Epidemiology, 2017) 
Service Planning Area 1 
Acton 
Del Sur 
Gorman 
Hi Vista 
Lake Hughes 
Lake Los Angeles 
Lancaster 
Leona Valley 
Littlerock 
Liano 
Palmdale 
Pearblossom 
  
Quartz Hill 
South Antelope 
Valley 
Valyermo 
Service Planning Area 2 
Agoura Hills 
Burbank 
Calabasas 
Canoga Park 
Canyon Country 
Castaic 
Chatsworth 
Encino 
Glendale 
Hidden Hills 
La Canada-Flintridge 
Northridge 
Pacoima 
Reseda 
Sand Canyon 
San Fernando 
Santa Clarita 
Saugus 
Sepulveda 
Sherman Oaks 
Stevenson Ranch 
Sunland 
Sun Valley 
Sylmar 
Tujunga 
Universal City 
Valencia 
Van Nuys 
West Hills 
Westlake Village 
Woodland Hills 
Service Planning Area 3 
Alhambra 
Altadena 
Arcadia 
Azusa 
Baldwin Park 
Bradbury 
Citrus 
City of Industry 
Claremont 
Covina 
Diamond Bar 
Duarte 
El Monte 
Glendora 
Hacienda Heights 
Irwindale 
La Puente 
La Verne 
Monrovia 
Monterey Park 
Pasadena* 
Pomona 
Rosemead 
San Dimas 
San Gabriel 
San Marino 
Sierra Madre 
South El Monte 
Temple City 
Valinda 
Walnut 
West Covina 
Service Planning Area 4 
Eagle Rock 
El Sereno 
Hollywood 
Downtown Los Angeles 
Mid-City Los Angeles 
Mount Washington 
Park La Brea 
West Hollywood 
Service Planning Area 5 
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Beverly Hills 
Brentwood 
Culver City 
Malibu 
Pacific Palisades 
Playa del Rey 
Santa Monica 
Venice 
Service Planning Area 6 
Athens 
Compton 
Crenshaw 
Florence 
Hyde Park 
Lynwood 
Paramount 
Watts 
Service Planning Area 7 
Artesia 
Bellflower 
Bell Gardens 
Cerritos 
City of Commerce 
Downey 
East Los Angeles 
Hawaiian Gardens 
Huntington Park 
La Habra Heights 
Lakewood 
La Mirada 
Lynwood 
Montebello 
Norwalk 
Paramount 
Pico Rivera 
Santa Fe Springs 
South Gate 
Vernon 
Whittier 
Service Planning Area 8 
Avalon 
Carson 
Catalina Island 
El Segundo  
Gardena 
Hawthorne 
Inglewood 
Lennox 
Lomita 
Long Beach* 
Hermosa Beach 
Manhattan Beach 
Naples 
Palos Verdes Estates 
Rancho Palos Verdes 
Redondo Beach 
Rolling Hills 
San Pedro 
Signal Hill 
Wilmington  
*The cities of Long Beach and Pasadena are not served by the Los Angeles County 
Department of Public Health, as each of these cities has its own health department. 
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Determinants of health per category with no statistically significant distinction of better or 
worse outcomes: 
Gender, age group, race, foreign born, marital status, disabled, sexual orientation, education, 
employment status, poverty as defined by the Federal Poverty Level, and access to mental 
healthcare.     
 
Determinants of health per category with statistically significant distinction of better or 
worse outcomes:  
Housing, food, neighborhood, air quality, climate change, school readiness, television viewing, 
parental support, breastfeeding, childcare, community, health-related quality of life, special 
health care needs, insurance, regular source to care, access to medical care, access to dental care, 
women’s health, immunizations, alcohol and drug use, nutrition, tobacco use, physical activity, 
overweight and obesity, diabetes, cardiovascular disease, reproductive health, injury, mental 
health, communicable diseases, respiratory disease, cancer, and all-cause mortality.  
 
The following is a migraine-oriented, curated list of the category’s sub-category that was 
found to be statistically different from the SPA as a cohort when determining better or 
worse outcomes:  
  
SPA 1  
High Housing instability – 11.3% 
No parks – 27.9% 
Number of days poor health limited physical activity – 3.2% 
Number of unhealthy days – 7.4% 
Adults receiving enough emotional support – 71.5% 
Adults who smoke cigarettes – 18.2% 
Adults who drink at least one soda or sweetened drink a day – 37.4% 
Adult obesity – 29.6% 
Adults with T2DM – 13.9% 
Adults with HTN – 30.3% 
Suicide rate – 8.6% 
Unintentional drug-related death rate – 12.2 
Adults with depression – 12.5% 
Alzheimer’s disease death rate – 40.8% 
All-cause mortality – 775.8 
Low Adults exercising in neighborhood – 35.3% 
Incidence of HIV/AIDS – 13.2% 
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SPA 2  
High Adults exercising in neighborhood – 50.4% 
Adults receiving enough emotional support – 69.1% 
Adults with HTN –8.6% 
 
 
Low Housing instability – 3% 
No parks – 12.9% 
Health is fair/poor – 17.5% 
Adults who did not see a dentist in the last year – 34.9% 
Adults who drink at least one soda or sweetened drink a day – 28.0% 
Adult obesity – 19.8% 
Adults with T2DM – 4.5% 
Incidence of HIV/AIDS – 15.2% 
All-cause mortality – 574.4 
Adults who misused prescription drugs in the past year – 3.9% 
 
 
 
SPA 3  
High Adults with depression – 6.4% 
Low Food insecure – 21.8 
No parks – 12.5% 
Adults receiving enough emotional support – 55.5% 
Adults with HTN – 6.9% 
Unintentional drug-related death rate – 4.5 
Incidence of HIV/AIDS – 1.2% 
All-cause mortality – 562.2 
 
 
 
 
SPA 
4 
 
High No parks 19.2% 
Difficulty accessing medical care – 28.6% 
Unintentional drug-related death rate – 8.8 
Adults with depression – 10.8% 
Incidence of HIV/AIDS – 69.6% 
Low Alzheimer’s disease death rate – 19.1% 
Adults insured – 84.8%  
All-cause mortality – 552.3 
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SPA 5  
High Safe from crime – 97.4% 
Adults exercising in neighborhood – 50.4% 
Adults receiving enough emotional support – 74.8% 
Adults insured – 95.3%  
Adults who achieve recommended exercise activity – 73.4% 
Unintentional drug-related death rate – 8.6 
Low Health is fair/poor – 10% 
Number of days poor health limited physical activity – 3.2% 
Difficulty accessing medical care – 13.1% 
Adults who did not see a dentist in the last year – 28.9% 
Adults who smoke cigarettes – 8.3% 
Adults who drink at least one soda or sweetened drink a day – 21.7% 
Adult obesity – 10.3% 
Adults with T2DM – 4.5% 
Adults with HTN – 17.1% 
Alzheimer’s disease death rate – 23.3% 
Incidence of HIV/AIDS – 16.7% 
All-cause mortality – 483.3 
 
 
 
 
Spa 6  
High Housing instability – 11.3% 
No parks – 19.2% 
Health is fair/poor – 17.5% 
Difficulty accessing medical care – 32.5% 
Adults who did not see a dentist in the last 56.9% 
Adults who drink at least one soda or sweetened drink a day – 41.9% 
Adult obesity – 34.1% 
Adults with T2DM – 12.3% 
Unintentional drug-related death rate – 8.7 
Incidence of HIV/AIDS – 35.1% 
All-cause mortality – 726.6 
Low Area safe from crime – 40% 
Adults exercising in neighborhood – 39.4% 
Adults receiving enough emotional support – 55.7% 
Adults insured – 82.2%  
Adults with HTN – 4.1% 
Alzheimer’s disease death rate – 22.0% 
 
 
 
 
 
 39 
SPA 7  
High Adults who did not see a dentist in the last year – 46.9% 
Adults who drink at least one soda or sweetened drink a day – 40.3% 
Adult obesity – 28.0% 
All-cause mortality – 604.2 
 
Low Unintentional drug-related death rate – 5.1 
Alzheimer’s disease death rate – 23.1% 
Incidence of HIV/AIDS – 15.7% 
 
 
 
 
SPA 8  
High Adults with HTN – 9.0% 
Unintentional drug-related death rate – 8.0 
All-cause mortality – 624.1 
Low Difficulty accessing medical care – 19.1% 
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Appendix B 
The Structured Field Staff Satisfaction Questionnaire (Not implemented due to COVID-19) 
Question Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
1) The 
structured 
fields are 
easy to use. 
     
2) The 
discrete data 
fields are 
useful for the 
clinic. 
     
3) The 
discrete data 
fields take 
too long to 
fill out. 
     
 
 
Do you have any suggestions to improve this process? 
 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
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Appendix C 
Migraine Demographic Data Questionnaire, part 1.  
Please place an x next to your answer where applicable.   
 
Highest level of education completed:  _ Elementary   _Graduate  
_ Middle School  _Baccalaureate 
      _High School   _Doctoral 
      _None of the above  _ Post-Doctoral  
       
 
Yearly household income: _ Under 15,000 per year 
    _ 15,000 – 24,999 
    _ 25,000 – 34,999 
    _ 35,000 – 49,999 
    _ 50,000 – 74,999 
    _ 75,000 – 99,999 
    _ 100,000 – 149,999 
    _ 150,000 – 199,999 
    _ 200,000 and over 
 
Preferred language for healthcare: _________________ 
 
Marital status: _ Single 
  _ Married 
  _ Domestic Partnership 
  _ Widowed 
  _ Divorced  
  _ Separated  
  _ Other 
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Appendix D 
Migraine Demographic Data Questionnaire, part 2.  
1. Age 
2. Gender 
3. Last documented blood pressure 
4. Last documented weight 
5. Last documented height 
6. Zip code 
7. Insurance: commercial, government sponsored (Tricare, Medical, Medicare) or none 
8. Age of migraine onset 
9. Average number of migraine frequency 
10. Average severity of migraine attack  
11. Number of preventive medications tried 
12. Number of migraine preventive medications currently used 
13. Number of acute therapies tried 
14. Number of acute migraine therapies currently used 
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Appendix E 
Migraine Demographic Data Questionnaire, part 1 – Codified.  
 
1. Highest level of education completed:   
a. 1 = Elementary 
b. 2 = Middle School  
c. 3 = High School  
d. 4 = Baccalaureate  
e. 5 = Graduate  
f. 6 = Doctoral 
g. 7 = Post-Doctoral 
h. 8 = None of the above  
     
2. Yearly household income:  
a. 0 = Under 15,000 per year 
b. 1 = 15,000 – 24,999 
c. 2 = 25,000 – 34,999 
d. 3 = 35,000 – 49,999 
e. 4 = 50,000 – 74,999 
f. 5 = 75,000 – 99,999 
g. 6 = 100,000 – 149,999 
h. 7 = 150,000 – 199,999 
i. 8 = 200,000 and over 
 
3. Preferred language for healthcare 
a. 0 = English 
b. 1 = Spanish 
c. 2 = Other 
 
4. Marital status:  
a. 1 = Single 
b. 2 = Married 
c. 3 = Domestic Partnership 
d. 4 = Widowed 
e. 5 = Divorced  
f. 6 = Separated  
g. 7 = Other 
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Appendix F 
Migraine Demographic Data Questionnaire, part 2 – codified 
15. Age  
16. Gender  
a. 0 = female  
b. 1 = male 
17. Last documented blood pressure  
18. Last documented weight   
19. Last documented height   
20. Zip code  
a. 1 = SPA 1  
b. 2 = SPA 2  
c. 3 = SPA 3  
d. 4 = SPA 4  
e. 5 = SPA 5  
f. 6 = SPA 6  
g. 7 = SPA 7 
h. 8 = SPA 8 
i. 9 = Zip code is not part of Los Angeles County 
21. Insurance 
a. 0 = Commercial insurance – HMO, PPO  
b. 1 = State or federally sponsored insurance – Medical, Medicare,  
22. Age of migraine onset   
23. Average number of migraine frequency   
24. Average severity of migraine attack    
25. Number of preventive medications tried (including current preventives used)  
26. Number of migraine preventive medications currently used   
27. Number of acute therapies tried   
28. Number of acute migraine therapies currently used  
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Appendix G 
Examples Participant Calendars/Diaries.  
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 48 
April 2020 – four days migraine-free. Highlighted days are no triptan days.  
SUNDAY MONDAY TUESDAY WEDNESDAY THURSDAY FRIDAY SATURDAY 5	
fish oil w/meal 
   300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
    200 Celebrex 
   400 magnesium 
     10 Memantine     	
6	
fish oil w/meal 	300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
    200 Celebrex 
   400 magnesium 
     10 Memantine      
 
7		
fish oil w/meal	
   300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine   
8		
fish oil w/meal	
   300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine   
9		
fish oil w/meal	
   300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine     
10 
fish oil w/meal        
   300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine   
11		
fish oil w/meal	
  300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine   
12		
fish oil w/meal	
   300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine  
  
 
13		
fish oil w/meal	
   300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine   
 
14		
fish oil w/meal	
   300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine   
15		
fish oil w/meal	
   300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine   
16		
fish oil w/meal	
   300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine   
17	
fish oil w/meal	
   300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine     
      
18	
fish oil w/meal	
   300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine      
19		
fish oil w/meal	
   300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine      
   
20		
fish oil w/meal	
 300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine   
       
21	AJOVY	
fish oil w/meal	
   300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine     
 
22	
fish oil w/meal	
  300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine   
      
23		
fish oil w/meal	
  300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine   
24	
fish oil w/meal	
      300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine   
25		
fish oil w/meal	
 300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine   
26		
fish oil w/meal	
  300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine  	
27	
fish oil w/meal	
    300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine   
 
28		
fish oil w/meal	
  300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
   200 Celebrex 
   400 magnesium 
     10 Memantine   
29		
fish oil w/meal	
  300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
    
   400 magnesium 
     10 Memantine   
30		
fish oil w/meal	
     300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
    
   400 magnesium 
     10 Memantine   
 
5/1	
fish oil w/meal	
     300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
    
   400 magnesium 
     10 Memantine   
 
5/2	
fish oil w/meal	
  300 co-q 10 
   400 magnesium 
   200 Celebrex 
     10 Memantine 
fish oil w/meal 
    
   400 magnesium 
     10 Memantine   
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Appendix H 
Migraine headache day structured field, beta version  
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